Search Results - "de Langen, J."

Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer by Niemeijer, A. N., Leung, D., Huisman, M. C., Bahce, I., Hoekstra, O. S., van Dongen, G. A. M. S., Boellaard, R., Du, S., Hayes, W., Smith, R., Windhorst, A. D., Hendrikse, N. H., Poot, A., Vugts, D. J., Thunnissen, E., Morin, P., Lipovsek, D., Donnelly, D. J., Bonacorsi, S. J., Velasquez, L. M., de Gruijl, T. D., Smit, E. F., de Langen, A. J.

“…PD-L1 immunohistochemistry correlates only moderately with patient survival and response to PD-(L)1 treatment. Heterogeneity of tumor PD-L1 expression might…”
Get full text

Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications by de Langen, Adrianus J., Smit, Egbert F.

“…Lung adenocarcinoma is known for its high rate of somatic mutations and genomic rearrangements. The identification of epidermal growth factor receptor (EGFR)…”
Get full text

Repeatability of Radiomic Features in Non-Small-Cell Lung Cancer [18F]FDG-PET/CT Studies: Impact of Reconstruction and Delineation by van Velden, Floris H. P., Kramer, Gerbrand M., Frings, Virginie, Nissen, Ida A., Mulder, Emma R., de Langen, Adrianus J., Hoekstra, Otto S., Smit, Egbert F., Boellaard, Ronald

“…Purpose To assess (1) the repeatability and (2) the impact of reconstruction methods and delineation on the repeatability of 105 radiomic features in…”
Get full text

Exposure–Response Analysis of Osimertinib in EGFR Mutation Positive Non-Small Cell Lung Cancer Patients in a Real-Life Setting by Boosman, René J., Jebbink, Merel, Veldhuis, Wouter B., Groenland, Stefanie L., van Veggel, Bianca A. M. H., Moeskops, Pim, de Langen, Adrianus J., Beijnen, Jos H., Smit, Egbert F., Huitema, Alwin D. R., Steeghs, Neeltje

“…Background Osimertinib, an irreversible inhibitor of the epidermal growth factor receptor (EGFR) is an important drug in the treatment of EGFR-mutation…”
Get full text

Early response evaluation of PD-1 blockade in NSCLC patients through FDG-PET-CT and T cell profiling of tumor-draining lymph nodes by Borm, Frank J, Smit, Jasper, Bakker, Joyce, Wondergem, Maurits, Smit, Egbert F, de Langen, Adrianus J, de Gruijl, Tanja D

“…Better biomarkers for programmed death - (ligand) 1 (PD-(L)1) checkpoint blockade in non-small cell lung cancer (NSCLC) are needed. We explored the predictive…”
Get full text

A two-center comparative study of gastric pull-up and jejunal interposition for long gap esophageal atresia by Gallo, Gabriele, Zwaveling, Sander, Van der Zee, David C, Bax, Klaas N, de Langen, Zacharias J, Hulscher, Jan B.F

“…Abstract Purpose When restoration of the anatomical continuity in case of long gap esophageal atresia (LGEA) is not feasible, esophageal replacement surgery…”
Get full text

Clinical Relevance of High Plasma Trough Levels of the Kinase Inhibitors Crizotinib, Alectinib, Osimertinib, Dabrafenib, and Trametinib in NSCLC Patients by Lin, Lishi, Barkman, Hannerieke J., Smit, Egbert F., de Langen, Adrianus J., Steeghs, Neeltje, Beijnen, Jos H., Huitema, Alwin D. R.

“…the study aims to evaluate whether high plasma trough levels of the kinase inhibitors (K.I.s) crizotinib, alectinib, osimertinib, dabrafenib, and trametinib…”
Get full text

Relationship between Biodistribution and Tracer Kinetics of 11C-Erlotinib, 18F-Afatinib and 11C-Osimertinib and Image Quality Evaluation Using Pharmacokinetic/Pharmacodynamic Analysis in Advanced Stage Non-Small Cell Lung Cancer Patients by van de Stadt, Eveline Annette, Yaqub, Maqsood, Schuit, Robert C., Bartelink, Imke H., Leeuwerik, Anke F., Schwarte, Lothar A., de Langen, Adrianus J., Hendrikse, Harry, Bahce, Idris

“…Background: Patients with non-small cell lung cancer (NSCLC) driven by activating epidermal growth factor receptor (EGFR) mutations are best treated with…”
Get full text

Repeatability of [18F]FDG PET/CT total metabolic active tumour volume and total tumour burden in NSCLC patients by Kolinger, Guilherme D., Vállez García, David, Kramer, Gerbrand M., Frings, Virginie, Smit, Egbert F., de Langen, Adrianus J., Dierckx, Rudi A. J. O., Hoekstra, Otto S., Boellaard, Ronald

“…Background Total metabolic active tumour volume (TMATV) and total tumour burden (TTB) are increasingly studied as prognostic and predictive factors in…”
Get full text

Dichotomous ALK-IHC Is a Better Predictor for ALK Inhibition Outcome than Traditional ALK-FISH in Advanced Non-Small Cell Lung Cancer by van der Wekken, A J, Pelgrim, R, 't Hart, N, Werner, N, Mastik, M F, Hendriks, L, van der Heijden, E H F M, Looijen-Salamon, M, de Langen, A J, Staal-van den Brekel, J, Riemersma, S, van den Borne, B E, Speel, E J M, Dingemans, A-M C, Hiltermann, T J N, van den Berg, A, Timens, W, Schuuring, E, Groen, H J M

“…ALK rearrangement detection using FISH is the standard test to identify patients with non-small cell lung carcinoma (NSCLC) eligible for treatment with ALK…”
Get full text

Biliary Atresia in The Netherlands: Outcome of Patients Diagnosed between 1987 and 2008 by de Vries, Willemien, MD, PhD, de Langen, Zacharias J., MD, PhD, Groen, Henk, MD, PhD, Scheenstra, Rene, MD, PhD, Peeters, Paul M.J.G., MD, PhD, Hulscher, Jan B.F., MD, PhD, Verkade, Henkjan J., MD, PhD

“…Objective To examine the outcome of biliary atresia (BA) and to identify prognostic factors using a national database. Study design All children born between…”
Get full text

Verapamil reduces tachycardia-induced electrical remodeling of the atria by TIELEMAN, R. G, DE LANGEN, C. D. J, VAN GELDER, I. C, DE KAM, P. J, GRANDJEAN, J, BEL, K. J, WIJFFELS, M. C. E. F, ALLESSIE, M. A, CRIJNS, H. J. G. M

“…Prolonged periods of atrial fibrillation or rapid atrial pacing induce shortening of the atrial effective refractory period (AERP), which is thought to be…”
Get full text

Hypofractionated radiotherapy combined with targeted therapy or immunotherapy: Dutch survey on current practice, knowledge and challenges by van Aken, Evert S.M., van der Linden, Yvette M., van Thienen, Johannes V., de Langen, Adrianus J., Marijnen, Corrie A.M., de Jong, Monique C.

“…•Radiotherapy referral during targeted therapy or immunotherapy occurs regularly.•There is a knowledge gap regarding the implications of combined…”
Get full text

Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancer by van Berge Henegouwen, J.M., Jebbink, M., Hoes, L.R., van der Wijngaart, H., Zeverijn, L.J., van der Velden, D.L., Roepman, P., de Leng, W.W.J., Jansen, A.M.L., van Werkhoven, E., van der Noort, V., van der Wekken, A.J., de Langen, A.J., Voest, E.E., Verheul, H.M.W., Smit, E.F., Gelderblom, H.

“…In 1–3% of non-small cell lung cancer (NSCLC) human epidermal growth factor 2 (HER2) mutations are identified as a genomic driver. Nevertheless, no…”
Get full text

Resistance Mechanisms to AZD9291 and Rociletinib-Letter by Van Der Steen, Nele, Rolfo, Christian, Pauwels, Patrick, de Langen, Adrianus J, Peters, Godefridus J, Giovannetti, Elisa

Get full text

Representativeness of Phase III Trial for Osimertinib in Pretreated Advanced EGFR-Mutated Non-small-cell Lung Cancer Patients and Treatment Outcomes in Clinical Practice by Lin, Lishi, Smit, Egbert F., de Langen, Adrianus J., van Balen, Dorieke E. M., Beijnen, Jos H., Huitema, Alwin D. R.

“…Background Overall survival (OS) data of osimertinib in pretreated non-small-cell lung cancer (NSCLC) in real-world practice is limited, and treatment benefits…”
Get full text

Real-World Approach for Molecular Analysis of Acquired EGFR Tyrosine Kinase Inhibitor Resistance Mechanisms in NSCLC by Hondelink, Liesbeth M., Jebbink, Merel, von der Thüsen, Jan H., Cohen, Danielle, Dubbink, Hendrikus J., Paats, Marthe S., Dingemans, Anne-Marie C., de Langen, Adrianus J., Boelens, Mirjam C., Smit, Egbert F., Postmus, Pieter E., van Wezel, Tom, Monkhorst, Kim

“…With the approval of first-line osimertinib treatment in stage IV EGFR-mutated NSCLC, detection of resistance mechanisms will become increasingly important—and…”
Get full text

Stage I non-small cell lung cancer: Treatment modalities, Dutch daily practice and future perspectives by Hopstaken, Jana S., de Ruiter, Julianne C., Damhuis, Ronald A.M., de Langen, Adrianus J., van Diessen, Judi N.A., Klomp, Houke M., Klompenhouwer, Elisabeth G., Hartemink, Koen J.

“…•Anatomical resection with lymph node dissection is recommended for stage i NSCLC.•Despite several trials, the role of SABR in operable patients is not clear…”
Get full text

Nonsmall cell lung carcinoma: diagnostic difficulties in small biopsies and cytological specimens by Lukas Bubendorf, Sylvie Lantuejoul, Adrianus J. de Langen, Erik Thunnissen

“…The pathological and molecular classification of lung cancer has become substantially more complex over the past decade. For diagnostic purposes on small…”
Get full text

High PD-1 expression on regulatory and effector T-cells in lung cancer draining lymph nodes by van de Ven, Rieneke, Niemeijer, Anna-Larissa N, Stam, Anita G M, Hashemi, Sayed M S, Slockers, Christian G, Daniels, Johannes M, Thunnissen, Erik, Smit, Egbert F, de Gruijl, Tanja D, de Langen, Adrianus J

“…The treatment of advanced nonsmall cell lung cancer (NSCLC) with PD-1/PD-L1 immune checkpoint inhibitors has improved clinical outcome for a proportion of…”
Get full text